X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (5) 5
index medicus (5) 5
lung cancer (5) 5
humans (4) 4
oncology (4) 4
aged (3) 3
apoptosis (3) 3
cancer (3) 3
care and treatment (3) 3
cisplatin (3) 3
female (3) 3
immunotherapy (3) 3
lung neoplasms - drug therapy (3) 3
lung neoplasms - pathology (3) 3
male (3) 3
middle aged (3) 3
survival (3) 3
tumors (3) 3
carboplatin (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
cisplatin - administration & dosage (2) 2
clinical trials (2) 2
disease-free survival (2) 2
drug administration schedule (2) 2
drugs (2) 2
epidermal growth factor receptors (2) 2
etoposide (2) 2
gefitinib (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - mortality (2) 2
medicine & public health (2) 2
metaanalysis (2) 2
neutropenia (2) 2
non-small cell lung carcinoma (2) 2
product development (2) 2
prophylactic cranial irradiation (2) 2
quinazolines - therapeutic use (2) 2
radiation (2) 2
receptor, epidermal growth factor - genetics (2) 2
sclc (2) 2
therapy (2) 2
treatment outcome (2) 2
1st-line treatment (1) 1
abridged index medicus (1) 1
adenocarcinoma (1) 1
adjuvants (1) 1
administration, oral (1) 1
advanced nsclc (1) 1
adverse events (1) 1
agriculture (1) 1
algorithms (1) 1
analysis (1) 1
anemia (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic agents, phytogenic - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis - drug effects (1) 1
apoptosis - genetics (1) 1
apoptosis regulatory proteins - genetics (1) 1
apoptosis regulatory proteins - metabolism (1) 1
article (1) 1
bcl-2-like protein 11 (1) 1
bim protein (1) 1
biomarker (1) 1
brca1 (1) 1
cancer research (1) 1
cancer therapies (1) 1
carboplatin - adverse effects (1) 1
carboplatin/paclitaxel (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
cell activation (1) 1
cell death (1) 1
cell proliferation (1) 1
chi-square distribution (1) 1
cisplatin - adverse effects (1) 1
clinical medicine (1) 1
cohort studies (1) 1
data processing (1) 1
deoxycytidine - administration & dosage (1) 1
deoxycytidine - analogs & derivatives (1) 1
disease (1) 1
disease progression (1) 1
double-blind (1) 1
doublet chemotherapy (1) 1
drug therapy (1) 1
erlotinib (1) 1
erlotinib hydrochloride (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
by Paz-Ares, Luis and Dvorkin, Mikhail and Chen, Chengshui and Chen, Yen-Hsun and Chen, Yuan and Chen, Yuanbin and Chen, Zhendong and Reinmuth, Niels and Hotta, Katsuyuki and Trukhin, Dmytro and Statsenko, Galina and Hochmair, Maximilian J and Özgüroğlu, Mustafa and Ji, Jun Ho and Voitko, Nataliia and Voitko, Oleksandr and Poltoratskiy, Artem and Ponce, Santiago and Verderame, Francesco and Havel, Libor and Bondarenko, Igor and Kazarnowicz, Andrzej and Losonczy, György and Conev, Nikolay V and Armstrong, Jon and Byrne, Natalie and Shire, Norah and Jiang, Haiyi and Goldman, Jonathan W and Batagelj, Emilio and Casarini, Ignacio and Pastor, Anea Viviana and Sena, Susana Noemi and Zarba, Juan Jose and Burghuber, Otto and Hartl, Sylvia and Lamprecht, Bernd and Studnicka, Michael and Alberto Schlittler, Luis and Augusto Martinelli de Oliveira, Fabricio and Calabrich, Aknar and Colagiovanni Girotto, Gustavo and Dos Reis, Peo and Fausto Nino Gorini, Carlos and Rafael Martins De Marchi, Peo and Serodio da Rocha Baldotto, Clarissa and Sette, Claudia and Zukin, Mauro and Dudov, Assen and Ilieva, Rumyana and Koynov, Krassimir and Krasteva, Rositsa and Tonev, Ivan and Valev, Spartak and Venkova, Violetka and Bi, Minghong and Fang, Jian and Feng, Jifeng and Han, Zhigang and Hu, Jie and Hu, Yi and Li, Wei and Li, Chien-Te and Liang, Zongan and Lin, Zhong and Ma, Shenglin and Ma, Rui and Nan, Kejun and Shu, Yongqian and Wang, Chin-Chou and Wang, Kai and Wang, Mengzhao and Wu, Gang and Wu, Shang-Yin and Yang, Nong and Yang, Zhixiong and Zhang, Wei and Zhang, Helong and Zhao, Yanqiu and Zhao, Jun and Zhou, Jianying and Zhou, Caicun and Zhou, Xiangdong and Kolek, Vitezslav and Koubkova, Leona and Roubec, Jaromir and Skrickova, Jana and Zemanova, Milada and Chouaid, Christos and Hilgers, Werner and Lena, Hervé and Moro-Sibilot, Denis and Robinet, Gilles and Souquet, Pierre-Jean and Alt, Jürgen and Bischoff, Helge and Grohe, Christian and Laack, Eckart and Lang, Susanne and Panse, Jens and ... and CASPIAN Investigators and CASPIAN investigators
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1929 - 1939
Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has... 
PROPHYLACTIC CRANIAL IRRADIATION | SCLC | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CISPLATIN | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Etoposide - adverse effects | Drug Administration Schedule | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Carboplatin - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Progression-Free Survival | Cisplatin - adverse effects | Female | Small Cell Lung Carcinoma - mortality | Aged | Etoposide | Care and treatment | Product development | Lung cancer | Analysis | Drugs | Medical services | Radiation | Clinical trials | Metastasis | Cancer therapies | Randomization | Motivation | Platinum | Immunotherapy | Safety | Neutropenia | Small cell lung carcinoma | Maintenance | Radiation therapy | Survival | Patients | Cisplatin | Response rates | Carboplatin | Irradiation | Ligands | Clinical medicine | Solid tumors | Tumors | Apoptosis
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2076 - 2084
Abstract Background The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and... 
Lefitolimod | SCLC | TLR9 agonist | Immunotherapy | SURVIVAL | REGULATORY B-CELLS | CHEMOTHERAPY | TRIAL | ONCOLOGY | immunotherapy | DISEASE | MGN1703 | DOUBLE-BLIND | SUNITINIB | PLUS ETOPOSIDE | lefitolimod | HEALTH | Original
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 17499
BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may... 
APOPTOSIS | THERAPY | MESSENGER-RNA EXPRESSION | EURTAC | MULTIDISCIPLINARY SCIENCES | KINASE | MUTATIONS | BRCA1 | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Middle Aged | Apoptosis - genetics | Lung Neoplasms - pathology | Male | RNA, Messenger - metabolism | TOR Serine-Threonine Kinases - genetics | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Inhibitory Concentration 50 | Female | Membrane Proteins - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Membrane Proteins - genetics | RNA, Messenger - genetics | Proto-Oncogene Proteins - genetics | Treatment Outcome | Signal Transduction - genetics | Mutation - genetics | Apoptosis Regulatory Proteins - metabolism | Disease-Free Survival | Signal Transduction - drug effects | Quinazolines - therapeutic use | Erlotinib Hydrochloride - pharmacology | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Cohort Studies | Tyrosine | TOR protein | Cell proliferation | Adenocarcinoma | Epidermal growth factor receptors | Lung cancer | Non-small cell lung carcinoma | Tumor cell lines | Gene expression | Kinases | Cell activation | Gefitinib | Protein-tyrosine kinase | BIM protein | Apoptosis | Phosphodiesterase
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.